Minimal residual disease (MRD) quantified after induction treatment of childhood acute lymphoblastic leukemia (ALL) predicts risk of relapse. It has been assumed that early relapses derive from a residual population of leukemic cells, which is still present after induction and that relapsed disease will consequently be more resistant to treatment. To test these hypotheses, we performed a prospective study on patients treated according to the frontline-trial ALL-BFM 2000, which used MRD response for risk-group stratification. Patients (n ¼ 45) showed a median time to relapse of 1.5 years. In 89% of patients at least one T-cell-receptor/immunoglobulin gene rearrangement chosen for initial MRD quantification remained stable; however, at least one of the preferred markers for MRD stratification at relapse was different to diagnosis in 50% of patients. A similar proportion of very early, early and late relapses appeared to gain a marker at relapse although backtracking-analysis revealed that in 77% of cases, the gained markers were present as small sub-clones at initial diagnosis. Comparing initial and relapse MRD response to induction, 38% of patients showed a similar, 38% a better and 25% a poorer response after relapse. These data demonstrate an unexpectedly high clonal heterogeneity among very early/early relapses and challenge some current assumptions about relapsed ALL.
Introduction
Minimal residual disease (MRD) quantified with highly sensitive methods after induction treatment in both frontline and relapse trials predicts outcome of children with acute lymphoblastic leukemia (ALL).
1,2 Therefore, MRD after induction has been used for therapy stratification and has been measured at additional defined time points during treatment. In current and future frontline and relapse ALL-BFM (Berlin-Frankfurt-Muenster) trials, T-cell receptor(TCR)/immunoglobulin (IG) gene rearrangements have been and will be used for MRD quantification. 3, 4 To minimize the chance of a false negative MRD result, knowledge about the stability of TCR/IG-markers is important. It is well known that TCR/IG gene rearrangements are clonal markers, which can be used to study leukemic cell populations present in patients and their clonal evolution, and selection during and after treatment. [5] [6] [7] [8] [9] [10] The implications for MRD testing of the instability of some TCR/IG-markers between initial and relapse diagnosis has been assessed in several retrospective studies resulting in recommendations to use two markers to minimize the chance of false negative results. Most of these studies also compared the stability of markers at different gene loci with the aim of developing guidelines for the choice of markers for MRD quantification. [11] [12] [13] [14] [15] [16] A few studies focusing on clonal evolution have detected and quantified the levels of selected TCR/IG markers gained at relapse in the initial diagnosis sample for small numbers of patients. 6, 11, 17, 18 The proportion of these backtracked small subpopulations detectable at diagnosis varied between 10 and 67%. In single patients, a slower response to treatment of those sub-clones compared with the main clone assessing the MRD kinetics during treatment was observed. 6, 11, 17, 18 The presence of small sub-populations in the initial leukemic blast population, which expand to create the main population at relapse was also shown in 70% of patients by a study assessing copy number alterations between initial and relapse diagnosis. 19 Several studies have suggested that TCR/IG marker changes are more likely to occur in late than in early relapses and that early relapses occur when the leukemia present at initial diagnosis is inherently resistant. Analysis of genomic markers showed that relapses of t(12;21) positive ALL are different from but related to the dominant clone at initial diagnosis with independent transforming events. This is consistent with a model of pre-leukemic clone caused by the ETV6/RUNX1 transcript and frequently good treatment responses for newly diagnosed and relapsed ALL involving this rearrangement. 18, 20, 21, 22 On the other hand, it has been hypothesized that early relapses derive from the dominant leukemic clone at initial diagnosis based on the known association of slow early molecular treatment response (MRD after induction) with poor outcome. 23, 24 Beside this assumption, a recent study showed that later relapses were associated with lower levels of the relapse clonal markers at diagnosis. 17 Moreover, it has been shown that leukemic cells are more resistant at relapse than compared with initial disease. 25, 26 However, genome wide studies suggest that a high diversity of genetic lesions are involved in relapse development including B-cell differentiation, cell cycle control and tumor suppression. 19, 27 Previous studies of MRD marker changes between diagnosis and relapse were limited by their retrospective nature based on availability of paired specimens and the paucity of data on quantitative levels or the MRD kinetics of main-and sub-clones between initial and relapse diagnosis.
This first prospective study is based on the MRD studies, which accompanied the frontline trial ALL-BFM 2000 and the relapse trials ALL-REZ BFM 96 and 2002 in Germany. The first aim was to assess our system of choosing the TCR/IG gene rearrangements for initial MRD quantification and to set up, if necessary, additional recommendations for biologically and clinically reliable MRD monitoring. The second aim was to determine whether a complete new screening for TCR/IG targets at relapse diagnosis is essential for a reliable MRD monitoring during relapse treatment. The third aim was to establish whether relapsed ALL generally shows more drug resistance than newly diagnosed leukemia in the same patients. Finally this project was also expected to aid in assessing the hypotheses that early relapses derive either from a resistant dominant clone or from sub-clones present in a higher extent at relapse diagnosis than sub-clones of late relapses. 17, 23 Our analysis included mainly patients who relapsed very early (during first 18 months after initial diagnosis: 49%, 22/45) and early (between 18 and 30 months: 24%, 11/45), so that late relapses (430 months: 27%, 12/45) are underrepresented. The current data demonstrate a high rate of clonal change and an unexpected high heterogeneity of MRD response to initial and relapse induction treatment in children with ALL.
Materials and methods

Patients and samples
The study aimed to include all patients who suffered a relapse after having been treated according to the ALL-BFM 2000 trial including the pilot phase. The patients had both their initial and relapse diagnosis between 1 August 1999 and 30 April 2004. Only protocol patients, older than 1 year at initial diagnosis and involved in the MRD studies in Germany were included. Seventy nine patients fulfilled these criteria. Twenty three of these patients, who were not registered in the ALL-REZ BFM studies, either due to relapse shortly after stem cell transplantation or death shortly after relapse were not included (as no bone marrow (BM) was available). For eight patients who suffered an isolated extramedullary relapse, extramedullary specimens were not available and in another three patients, the amount of sample was not sufficient for further analysis. Thus, 45 patients were left for inclusion in this study. BM samples were taken at initial and relapse diagnosis and at defined time points during treatment according to the schedules of the protocols. In patients with an isolated extramedullary relapse, leukemic cells were isolated from the extramedullary compartment at relapse diagnosis as previously described. 28 Thirty six patients had B-cell precursor (BCP) ALL and nine patients T-cell ALL. Two ALL had the fusion gene BCR-ABL or translocation t(9;22), four TEL-AML1 or translocation t(12;21) and one MLL-AF4 or translocation t(4;11). The median observation time was 1.5 years (range 0.6-3.8). More patient characteristics including gender, age at initial and relapse diagnosis, time point and site of relapse and initial and relapse risk group are described in Table 1 . Parents or/and children signed an informed consent to take part in this study. Both the frontline (ALL-BFM 2000) and relapse trials (ALL-REZ BFM 96 and 2002) were approved by institutional ethics committees. ) after week 5 (day 36) also received allogeneic stem cell transplantation .
1,31
Identification of clonal TCR/IG gene rearrangements Mononuclear cells were isolated by Ficoll density centrifugation from BM samples. Genomic DNA was extracted by QIAamp R DNA Blood Kit (Qiagen GmbH, Hilden, Germany) or by Puregene DNA-Isolation kit (Qiagen GmbH). DNA was stored at À20 1C. Quantity and quality of DNA was assessed via spectrophotometer and electrophoresis in a 1% agarose gel. Identification of patient specific clonal gene rearrangements at initial and at relapse diagnosis of complete immunoglobulin heavy chain (IGH), the immunoglobulin light chain (IGK: VkKde, intron-Kde), T-cell receptor gamma (TRG: VG-JG1.3./2.3, VG-JG1.1/2.1), and complete and incomplete T-cell receptor delta (TRD: VD-(DD)-JD1, DD2-JD1, VD2-DD3, DD2-DD3), T-cell receptor Vdelta2-Jalpha(VD2-JA 9, 29, 30, 48, 54, 55, 58, 61) was performed for both BCP-and T-cell ALL as previously described in detail. [32] [33] [34] [35] To confirm clonality of the identified product, homo-heteroduplex analysis was performed. 36 Clonal products were sequenced using the ABI PRISM one or multicapillary analyzer (Applied Biosystems, Darmstadt, Germany). Junctional regions were analyzed using commonly distributed hardcopies and sequences at IMGT (http://imgt.cines.fr), Vbase (http://vbase.mrc-cpe.cam.ac.uk) or IgBlast (http://www.ncbi. nlm.nih.gov/igblast/) databases.
Real-time quantitative PCR analysis and MRD marker selection
At least one allele-specific oligonucleotide was designed for each clonal gene rearrangement identified at initial or relapse diagnosis and tested for its specificity and sensitivity in combination with germline TaqMan probes and germline reverse or forward primers. To check or correct the MRD levels in follow-up samples for the quantity and quality of DNA, RQ-PCR analysis for the single copy genes albumin or b-globin were performed. RQ-PCR data were analyzed according to rules and recommendations of the MRD Task Force of the AIEOP/ BFM ALL-2000 MRD laboratories and own respective established intralaboratory experience and in the endphase of our study established guidelines of the following ESG-MRD-ALL currently renamed as EuroMRD, which have been systematically used since autumn 2003. 29, 37, 38 In the ALL-BFM 2000 and ALL-REZ BFM 96 and 2002 MRD studies, at least two sensitive markers were required and used to measure MRD. The minimum sensitivity, later within the study newly defined and specified as quantitative range, of 1x10 À4 limited the selection of possible IG/TCR rearrangements. According to Szczepanski et al. 15 markers from a gene locus with multiple TCR/IG gene rearrangements are less stable, in these cases we aimed at using all markers from a multiple rearranged loci and, if possible, an additional marker from another gene locus. Generally rearrangements of the IGK and the IGH locus were preferred, followed by TRD and than TRG.
3
The selection strategy for markers used for MRD quantification during initial and relapse treatment is summarized in Supplementary Table S1 .
Backtracking analyses
RQ-PCR MRD assays were performed for the markers gained at relapse to identify small sub-clones below the detection limits of the routine PCR used for initial screening at diagnosis. A dilution series was made using DNA from relapse diagnosis and a sensitivity of at least 10 À4 was aimed for the RQ-PCR so that the relapse marker could be both detected and quantified in BM DNA in initial diagnosis.
Statistical analysis
Data were analyzed using STATA (version 9.0, StataCorp., College Station, TX, USA) software. Proportions of patients between different groups of categorical variables were compared using w 2 or Fisher's exact test. To test for an increase or decrease in ordered categorical variables the w 2 -test for trend Patients with unknown data of a variable are excluded from the statistical test for this variable.
Clonal heterogeneity in early relapses C Eckert et al was used. To test differences in continuous variables between two groups, the Mann-Whitney test was used.
Results
Comparison of markers identified at initial and relapse diagnosis
We included in our prospective study 45 patients who suffered a relapse after treatment according to the ALL-BFM 2000 trial. In 33% (15/45) of patients all clonal TCR/IG gene rearrangements identified at initial diagnosis remained stable at relapse diagnosis and no additional clonal gene rearrangement was gained at relapse (stable pattern). The remaining 67% of patients showed at least one clonal change. In 38% (17/45) of patients at least one gain of a TCR/IG gene rearrangement was detected at relapse. In 53% (24/45) of patients at least one loss and in 16% (7/45) a V-V-replacement or a Vdelta2-Jalpha ongoing rearrangement product was seen at relapse. Eighty percent (36/45) of patients had at least two initial markers, which remained stable at relapse and at least one stable marker between initial and relapse diagnoses was seen in 91% (41/45) of patients. In 9% (4/45) of patients none of the TCR/IG rearrangements identified at initial diagnosis remained stable at relapse diagnosis (different pattern). The proportion of patients with stable pattern, both stable and changed markers or a different pattern between initial and relapse diagnosis are summarized in Figure 1a .
Stability of markers chosen for initial MRD quantification
Given our aim of evaluating and optimizing current recommendations, we also compared the clonal TCR/IG gene rearrangements, which were selected as MRD markers and used for MRD quantification in the frontline trial. The proportion of patients with stable markers, partially or completely changed markers are shown in Figure 1b . Beside a high stability of all MRD markers in 62% of patients, in a considerable proportion of patients, loss of markers or the result of an ongoing rearrangement process in addition to stability was seen, even in 11% (5/45) of the patients all MRD markers were lost or rearranged further at relapse. Four of these patients lost all MRD markers present at diagnosis. There was no additional stable marker, which could have been chosen for MRD assessment. In one patient one marker was lost and the second marker underwent an ongoing rearrangement process. In this patient one additional stable marker would have been available.
Backtracking analysis of gained markers
In 38% (17/45) of patients at least one gain (markers n ¼ 30, range 1-4 per patient) of a TCR/IG gene rearrangement was seen at relapse. In 13 of these 17 patients, we were able to perform MRD assays for these gained markers to reassess with a greater sensitivity whether the gained rearrangement was present as a small sub-clone at initial diagnosis. 
Marker stability/change and patient related, clinical characteristics
We analyzed the data to determine whether the marker stability/ change between initial and relapse diagnosis was associated with any patient related and/or clinical characteristics in our prospectively assessed patient cohort by comparing patients with a stable pattern between initial and relapse diagnosis (no changes in all markers identified; n ¼ 15) with the remainder Figure 2 Quantitative level of backtracked markers and time between initial and relapse diagnosis. Backtracking analysis of markers gained at relapse was performed to assess whether the gained rearrangements were already present as small sub-clones at initial diagnosis. In 77% (10/13) of patients 17 markers could be sensitively identified by RQ-PCR in BM DNA from initial diagnosis. In case of two backtracked markers the highest quantitative level was considered.
Backtracked quantitative values were assigned to one of four categories (y axis). The x axis demonstrates the time between initial and relapse diagnosis in months; arrows indicate the cutpoints for the time point of relapse (very early: o18 months from initial diagnosis, early: 18-30 months, late: 430 months).
Clonal heterogeneity in early relapses C Eckert et al who showed at least one clonal change of markers between initial and relapse diagnosis (n ¼ 30) (Table 1 ). There was no difference in gender, age at initial and relapse diagnosis, site of relapse, immunophenotype, common fusion genes, initial risk or relapse risk group between the two groups. There was weak evidence (P ¼ 0.092) that very early relapses are more likely to have a stable pattern than early and late relapses. There was also no evidence that the rate of marker gain, loss and ongoing rearrangement was different between patients with very early, early and late relapse ( Figure 3 : Fisher's exact and test for trend, respectively: gain P ¼ 0.46, P ¼ 0.51; loss P ¼ 0.37, P ¼ 0.60; ongoing changes P ¼ 0.36, P ¼ 0.14).
Comparison of early MRD responses in the frontline and relapse treatments
To learn more about clonal markers, treatment response and drug resistance, we compared the early MRD response to the initial treatment and to the relapse treatment for each patient. The treatments of the frontline and relapse protocol are different and not directly comparable. Therefore, we used the time points of MRD assessment and the MRD cutoff values that have been shown to be prognostically significant in both protocols [1] [2] [3] Table 2 ). We then rated the relapse MRD response as similar, better or poorer than the initial MRD response. The molecular response to initial and relapse treatment did not show a consistent relationship. Although 38% (9/24) of patients showed a similar early MRD response behavior at initial and relapse treatment, the majority (62%, 15/24) of patients showed a different early MRD response to relapse therapy. This effect was independent of the markers used. In only 50% (12/24) of patients identical markers for MRD monitoring were used, but even this subgroup included different combinations of good, intermediate and poor responses at initial and relapse diagnosis. In the second group of patients (29%, 7/45), a combination of new and original MRD markers was used for measuring the relapse molecular response. These patients showed an intermediate or poor initial molecular response and the responses at relapse also differed. In the third group of five patients, completely different markers were used for initial and relapse MRD monitoring. Four patients had an intermediate initial response and one a good response. Table 2 also shows additional relevant information about clonal stability and change (stable, loss, ongoing rearrangement) of MRD markers, small sub-clones identified via backtracking and relapse related characteristics are shown but reveals no pattern, which correlates with the MRD response at relapse.
To assess whether MRD levels can be different in dependency of marker selection, we looked for patients with different MRD values at the same time points using different markers and whether markers showing different MRD result are stable or non-stable markers. In our study, we identified three patients showing relevant differences in MRD levels at the same initial time points (Supplementary Figure S1) ; two with differences in markers, which remained stable between initial and relapse diagnosis and one patient with a difference between a stable marker and a marker, which underwent very early V-V-replacement during treatment.
Discussion
The current systematic study of a cohort of relapsed patients treated initially on ALL-BFM 2000 and then ALL-REZ BFM 96/ 2002 demonstrates that choice of MRD markers to measure initial MRD response was sufficient for a reliable MRD quantification with a low risk of a false negative result. Further, the study presents data, which show an unexpected high proportion of clonal changes between initial and relapse diagnosis in patients with a very early or early relapse and subsequent heterogeneity in MRD marker choice and different molecular response at initial and relapse diagnosis.
Markers chosen for MRD quantification at initial diagnosis show a high stability
The present study compares TCR/IG gene rearrangements actually chosen for MRD quantification in a cohort assessed systematically for early molecular response to frontline treatment. The proportion of patients with stable markers used for MRD was high (62%) when only markers chosen for quantification are considered compared with all possible markers identified at initial diagnosis (33%). In 89% of patients, at least one marker chosen for MRD quantification remained stable. This suggests that the processes used for selecting markers at diagnosis, which include the requirement for high sensitivity are quite effective. To broaden the choice of markers for a sensitive MRD quantification assay, additional gene loci as incomplete IGH, TCRB(beta), IGL(lambda) and Vk-Jk are now being included in the marker screening. It would be interesting in future studies, and helpful for marker selection, to ascertain at what MRD time point during treatment markers disappeared or at what time point MRD levels became different when measured with different markers and whether markers giving a different MRD result are stable or non-stable markers. Beside stability of a marker, the comparison of a MRD value for one time point assessed by this marker with other markers should be considered as well. MRD levels during treatment can be different because sub-clones with different resistant profiles are monitored or clonal evolution occurs during treatment. Figure 3 Proportion of patients with at least one marker gained (gain), lost (loss) or in ongoing rearrangement process (ongo) according to the time point of relapse. Proportion of patients with clonal change specified in either gain loss or result of an ongoing rearrangement process according to time point of relapse (very early: o18 months from initial diagnosis, early: between 18 and 30 months, late: 430 months). Gain, the gain of a new marker at relapse; loss, loss of an initial marker at relapse; ongo, the result of ongoing rearrangement process as V-V replacement for IGH locus or Vd to Ja for TCRdelta/alpha locus.
Clonal heterogeneity in early relapses C Eckert et al
The patient cohort included 36 BCP-ALL and nine T-cell ALL. The stability profile did not differ between both groups in our cohort. A separation of BCP-und T-cell ALL was not performed in the further final analyses, because numbers of patients are small to reach the required power. 14, 15 High proportion of clonal changes in very early and early relapses
Considering all TCR/IG-targets identified, very early/early relapses showed no differences in proportion of patients with a gain, loss or change of markers because of an ongoing rearrangement process compared with late relapses. Our observation that very early and early relapses have clonal changes as frequently as late relapses confirms data from other studies using TCR/IG gene rearrangements and copy number alteration, which described the clonal evolution, which occurs between initial and relapse diagnosis. 6, 14, 15, 27 Clinically important characteristics such as the timing of relapse have only rarely been considered in studies comparing copy number alteration between diagnosis and relapse. 27 We found that 90% of markers 'gained' at relapse could be detected at lower quantitative levels at initial diagnosis by RQ-PCR based backtracking analysis. Among the very early/ early subset of relapses with gained markers, 80% of patients had small sub-clones at diagnosis. This is a much higher proportion than we would have expected based on previous studies using clonal TCR/IG markers. 6, 7, 11, 17, 18 Other authors described the presence of sub-clones in a higher proportion of early on-therapy relapses as well.
6,17 However, we did not see an association between quantitative levels of a sub-clone at initial diagnosis and time point of relapse described by Choi et al. 6, 17 The postulated mechanism for relapse in ALL of clonal expansion of an initially resistant small sub-clone in that paper was based on a cohort of only eight patients in the backtracking analyses and only a subset of gained clonal markers was considered. Another study also did not see an association between time point of relapse (very early/early or late) and quantitative level of backtracked clonal markers among t(12;21) positive ALL. 7 The frequent presence of small sub-clones in very early/early relapses demonstrated by our study challenges the dogma that Table 2 Comparison of molecular response to induction treatment during frontline and relapse treatment, markers used for MRD monitoring and initial/relapse characteristics Compared initial and relapse molecular response to therapy, using three categories, similar response at initial and relapse diagnosis, better response at relapse diagnosis and poorer response at relapse diagnosis.
Clonal heterogeneity in early relapses C Eckert et al early relapses derive from resistant residual leukemia cells, which could not be eliminated by polychemotherapy. 22, 23 The detailed repertoire analysis of IGH rearrangements performed by Brisco et al. 39 on diagnosis samples also suggests that the population of leukemic cells present at diagnosis is quite heterogeneous with sub-clones in most ALL patients, not just those who go onto relapse. Future studies which aim at integrating new targeted molecules in high risk treatment arms should be aware that they might eliminate only those cell populations carrying biological features, which characterize only sub-populations, and that sub-clones without these features might experience a selection advantage during treatment. 40 One hypothesis which would explain our observations is that relapses (including very early relapses) are not caused by the poor responding dominant and stable clone but by a changed clone, which is present already at initial diagnosis as smaller sub-clone or/and which is formed by additional mutations during initial treatment.
In a small proportion of reappearance of disease, the diagnosis is not a relapse but a secondary ALL. This is a possibility for the four patients (9%) who presented with a completely different marker profile at relapse compared with diagnosis. We did not perform the more extensive genomic testing necessary to exclude secondary ALL; but these patients were included in a systematic study discussing the identification, incidence and treatment of possible secondary ALL. 41 Assuming that all four of these cases represent true relapses, they provide justification for re-screening patients for new markers at relapse.
MRD reduction during frontline and relapse treatment is very heterogeneous
Earlier studies have demonstrated a higher chemo-resistance at relapse. 25, 26 Further, it has been generally assumed that very early and early relapses arise from highly resistant residual cells as recently reviewed. 23 Even though we only compared 24 cases, we found a variety of combinations of good, intermediate and poor MRD responses to initial and relapse treatment. Possible reasons for this high heterogeneity in early molecular treatment response to initial and relapse treatment are the existence of several clones in varying size including small subclones at initial and relapse diagnosis, clonal evolution and selection of cells and populations during and partly after treatment and involvement of extramedullary compartments in relapse development (21%, 5/24). About 40% of relapses have an extramedullary compartment involved, which also might have played an important pathophysiological role since initial diagnosis. 31 Relapse might derive from a leukemic cell or clone hidden or proliferated at the same time as in the BM in an extramedullary compartment. 42 Klumper et al. 25 have demonstrated that leukemia cells obtained at relapse diagnosis were in vitro significantly more resistant to many chemotherapeutic agents compared with cells from the initial diagnosis of the same patient reflected by the clinical response to chemotherapy as well. We observed this expected increase in resistance in vivo in only 24% (6/24) of patients. An improvement of treatment response to relapse treatment was seen in 38% (9/24) of patients. The observations in our cohort do not support the assumption of a general increase in drug-resistance at relapse.
Is a re-screening at relapse diagnosis in ongoing MRD studies mandatory?
Ongoing MRD studies, which accompany frontline trials often continue to use TCR/IG rearrangements initially chosen as MRD markers for MRD monitoring during relapse treatment. However, our study demonstrates that frequently markers are lost, further rearranged or gained at relapse. Moreover, an initial clone may be present at lower proportions at relapse resulting in a lower sensitivity for RQ-PCR assay, so that marker would no longer be selected as a preferred marker for MRD monitoring after relapse. Whether an initial MRD marker is lost or the junctional region sequence changed could be checked by RQ-PCR in the sample of relapse diagnosis to decide whether marker can be used. But the gain of a new marker on the dominant clone at relapse would not be known without a complete new screening at relapse diagnosis. Our study confirms previous studies demonstrating the gain of markers at relapse and shows that this not only occurs in late relapses but also in early and very early relapses in 30-55% of patients. As in our study, the markers chosen for initial and relapse MRD quantification were identical in only 50% of patients, we recommend re-screening for markers at relapse diagnosis whenever possible.
Beside TCR/IG markers, it would be interesting and meaningful to evaluate new biologically important genomic markers, especially genomic deletions, as individual clonal or sub-clonal markers for monitoring of clonal disease burden and kinetics. The recent use of sequences of genomic breakpoints for fusion genes to design MRD tests for MLL rearrangement or TEL/AML1 fusion gene positive leukemias is a good example. 43, 44 In summary, considering a high proportion of very early/early relapses in our cohort, we observed a remarkable heterogeneity in both the pattern of clonal TCR/IG gene rearrangements between initial and relapse diagnosis and distribution of the prognostic relevant MRD response categories to initial and relapse induction treatment. In addition, this study provides evidence supporting our recommendation that patients with relapsed ALL are re-screened for MRD markers in future studies.
